Literature DB >> 10500082

Cyclooxygenase 2 selective inhibitors: panacea or flash in the pan?

U Beejay, M M Wolfe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10500082     DOI： 10.1016/s0016-5085(99)70358-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  6 in total

Review 1.  Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: evolutionary cues for novel "first-in-class" anti-inflammatory drug candidates: a reviewer's perspective.

Authors:  Geetha Mathew; M K Unnikrishnan
Journal:  Inflamm Res       Date:  2015-07-18       Impact factor: 4.575

2.  Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation.

Authors:  David Y Graham; Nicholas P Jewell; Francis K L Chan
Journal:  Am J Med Sci       Date:  2011-11       Impact factor: 2.378

Review 3.  Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.

Authors:  A J Matheson; D P Figgitt
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs.

Authors:  Kathleen Bennett; Mary Teeling; John Feely
Journal:  Eur J Clin Pharmacol       Date:  2003-08-27       Impact factor: 2.953

5.  Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study).

Authors:  Peter Rose; Christine Steinhauser
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

6.  Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors?

Authors:  J Ostrowski; T Wocial; H Skurzak; W Bartnik
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.